Novel Treatment Advances and Approaches in the Management of HER2-Positive Advanced Breast Cancer: Expert Strategies on the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. Additionally, in the later stages of HER2+ disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the HER2+ metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life.

Fortunately for patients with HER2-positive advanced breast cancer, several new agents have been recently approved. They have shown the ability to improve safety and efficacy outcomes in the approximately 40% of patients living with HER2-positive advanced breast cancer. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose breast cancer and its corresponding stage, and provide the best evidenced-based treatment that is available for patients. Between 15% and 20% of breast cancers cases worldwide are HER2-positive subtypes and therefore are eligible for HER2-targeting therapies. Therapy for advanced breast cancer is increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. Fortunately for these patients, new options have recently been approved that have shown the ability to greatly improve outcomes in patients with HER2-positive advanced breast cancer.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of HER2-positive advanced breast cancer in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations

  • Describe the molecular heterogeneity of breast cancer and review how novel treatment approaches are overcoming obstacles in the management of HER2+ disease

  • Compare and contrast the efficacy, safety and mechanisms of action of new and emerging therapies, including tyrosine kinase inhibitors and antibody-drug conjugates, for the treatment of HER2-positive advanced breast cancer

  • Evaluate the evolving role of emerging therapies in the management of HER2-positive advanced breast cancer who have failed two or more lines of therapy and have brain metastases

  • Explore strategies for anticipating, recognizing, and managing adverse events of new and emerging therapies in HER2-positive advanced breast cancer

  • Apply methods to enable optimal cost management of new and emerging therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, to be realized by multiple HER2-positive advanced breast cancer stakeholders including managed care organizations


Faculty: Mark D. Pegram, MD
Director, Breast Cancer Oncology Program
Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology
Stanford University School of Medicine
Stanford Cancer Institute


Dr. Pegram serves on as a consultant for AstraZeneca, Daiichi Sankyo, Genentech, Macrogenics, and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue